Roche signs $15 billion ADC deal with China's Hansoh

· Health · Switzerland · China

Swiss pharma Roche has struck one of the largest cross-border drug collaborations of the year with China's Hansoh Pharmaceutical, paying $400 million upfront and potentially up to $15 billion in milestone payments. The broad agreement covers several antibody-drug conjugates, a class of cancer therapies that attach a cytotoxic payload to an antibody targeting tumor cells. The deal deepens Roche's access to Chinese drug discovery at a time when China is proposing new restrictions on foreign acquisitions of critical biopharma technologies. It follows a wave of licensing deals in which global drugmakers buy rights to Chinese-developed candidates, and signals that large-scale partnering with Chinese biotech remains open even as M&A rules tighten.

Why it matters：The deal shows China remains a major source of drug candidates for global pharma even as Beijing tightens rules on foreign acquisitions, a balance that will shape cross-border licensing.

Key points

  • Roche pays $400 million upfront, with up to $15 billion in potential biobucks.
  • The agreement involves several antibody-drug conjugates.
  • It is among the largest cross-border pharma collaborations of the year.

Sources (original reporting)

More stories from this day